Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-03-30
2001-02-20
Criares, Theodore J. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S554000
Reexamination Certificate
active
06191163
ABSTRACT:
BACKGROUND OF THE INVENTION
Compounds of Formula I:
are structurally novel antiepileptic compounds that are highly effective anticonvulsants in animal tests (Maryanoff, B. E, Nortey, S. O., Gardocki, J. F., Shank, R. P. and Dodgson, S. P.
J. Med. Chem.
30, 880-887, 1987; Maryanoff, B. E., Costanzo, M. J., Shank, R. P., Schupsky, J. J., Ortegon, M. E., and Vaught J. L. Bioorganic & Medicinal Chemistry Letters 3, 2653-2656, 1993). These compounds are covered by U.S. Pat. No.4,513,006. One of these compounds 2,3:4,5-bis-O-(1-methylethylidene)-&bgr;-D-fructopyranose sulfamate known as topiramate has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. FAUGHT, B. J. WILDER, R. E. RAMSEY, R. A. REIFE, L D. KRAMER, G. W. PLEDGER, R. M. KARIM et. al., Epilepsia 36 (S4) 33, 1995; S. K. SACHDEO, R. C. SACHDEO, R. A. REIFE, P. LIM and G. PLEDGER, Epilepsia 36 (S4) 33, 1995), and is currently marketed for the treatment of simple and complex partial seizure epilepsy with or without secondary generalized seizures in approximately twenty countries including the United States, and applications for regulatory approval are presently pending in several additional countries throughout the world.
Compounds of Formula I were initially found to possess anticonvulsant activity in the traditional maximal electroshock seizure (MES) test in mice (SHANK, R. P., GARDOCKI, J. F., VAUGHT, J. L., DAVIS, C. B., SCHUPSKY, J. J., RAFFA, R. B., DODGSON, S. J., NORTEY, S. O., and MARYANOFF, B. E., Epilepsia 35 450-460, 1994). Subsequent studies revealed that Compounds of Formula I were also highly effective in the MES test in rats. More recently topiramate was found to effectively block seizures in several rodent models of epilepsy (J. NAKAMURA, S. TAMURA, T. KANDA, A. ISHII, K. ISHIHARA, T. SERIKAWA, J. YAMADA, and M. SASA, Eur. J. Pharmacol. 254 83-89, 1994), and in an animal model of kindled epilepsy (A. WAUQUIER and S. ZHOU, Epilepsy Res. 24, 73-77, 1996).
Clinical studies on topiramate have revealed previously unrecognized pharmacological properties which suggest that topiramate will be effective in lowering lipids in humans, particularly in overweight individuals.
DISCLOSURE OF THE INVENTION
Accordingly, it has been found that compounds of the following formula I:
wherein X is O or CH
2
, and R1, R2, R3, R4 and R5 are as defined hereinafter are useful in maintaining weight loss.
REFERENCES:
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 6071537 (2000-06-01), Shank
patent: 98/00130 (1998-08-01), None
Kyowa Hakko: “Topiramate” Drugs of the Future, ES, Barcelona, vol. 21 No. 4, 1996 pp. 463-465 XP002043895.
York D A (Reprint) Et Al. “Effects of topiramate on high fat diet-induced obesity” FASEB Journal, (Mar. 15, 2000) vol. 4, No. 4, pp. A431-A431 Publisher Federation Amer Soc Exp Biol, 9650 Rockville Pike, Bethesda MD XP000915192 the whole document.
Criares Theodore J.
Kim Jennifer
Ortho-McNeil Pharmaceutical , Inc.
Palo Ralph R.
LandOfFree
Anticonvulsant derivatives useful in lowering lipids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticonvulsant derivatives useful in lowering lipids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticonvulsant derivatives useful in lowering lipids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2575064